One of the biggest hits in type 2 diabetes treatment is glucagon-like peptide (GLP)-1 receptor agonists, which induce insulin production in beta-pancreatic cells while suppressing the secretion of glucagon. All big pharma have GLP-1 drugs on the market or their pipelines, including Sanofi, Eli Lilly, Roche, AstraZeneca and Boehringer Ingelheim. But Novo Nordisk is going a step further with the first oral version of a GLP-1 drug, which is now close to the market.
That call went unheeded, however, as preventative has managed to survive as a variant, albeit a much less popular one. A search on the Corpus of Contemporary American English finds preventive beating preventative by a ratio of about 6 to 1 in current written usage, across both academic and nonacademic texts. You can still get away with using preventative in standard English, but that extraneous syllable won't gain you anything, other than disdain from the sticklers.
Type 2 diabetes is by far the most common form (around 90% of all cases) and the one which is increasing the most. It primarily affects overweight people in middle age or later. It’s not uncommon for the affected person to also have a high blood pressure and an abnormal lipid profile. Gestational diabetes is a temporary special case of type 2 diabetes.
In type 2 diabetes, there also is a steady decline of beta cells that adds to the process of elevated blood sugars. Essentially, if someone is resistant to insulin, the body can, to some degree, increase production of insulin and overcome the level of resistance. After time, if production decreases and insulin cannot be released as vigorously, hyperglycemia develops.
Benari doesn’t want to remain an outlier, though. And perhaps surprisingly, many doctors and surgeons are starting to agree that surgery should be considered more than a last-resort remedy for weight loss. Instead, it should be seen as a crucial aspect of diabetes care, and quite possibly the best tool we have against the chronic, often worsening condition.
“I don’t do anything a little bit,” said Nadia Bolz-Weber, a speaker whose recovery from addiction led her to become an ultraprogressive Lutheran minister. “I think that whole ‘balance’ thing is just another thing society made up to make me feel bad about myself. I’m not going to be someone who’s not intense, that’s not going to happen. So I was intense about the way I drank and did drugs.”
Foods high in fiber: Research shows that 90 percent of the U.S. population doesn’t consume enough fiber on a daily basis. High-fiber foods help slow down glucose absorption, regulate your blood sugar levels and support detoxification. Aim to eat at least 30 grams of fiber per day, which can come from vegetables (like Brussels sprouts, peas and artichokes), avocados, berries, nuts and seeds, especially chia seeds and flaxseeds. (9)
Benari, an Ashkenazi Jew, doesn’t fall into that category. But Cummings and other bariatric experts I spoke to said that surgery should be a possible option for any person whose diabetes isn’t improving. Cummings himself is currently working on a clinical trial in India of bariatric patients with BMIs as low as 25. And he expects similar trials will come down the pipeline.
If you bring your blood sugar into the healthy range (a hemoglobin A1C reading of 7% or lower), you'll reduce your risk of nerve damage by 60%, according to research from the National Institute of Diabetes and Digestive and Kidney Diseases. "Healthy blood sugar levels can slow the process and ease the pain of diabetic neuropathy," says Aaron I. Vinik, MD, PhD, the director of the research and neuroendocrine unit at Eastern Virginia Medical School.
You are more likely to develop type 2 diabetes if you are age 45 or older, have a family history of diabetes, or are overweight. Physical inactivity, race, and certain health problems such as high blood pressure also affect your chance of developing type 2 diabetes. You are also more likely to develop type 2 diabetes if you have prediabetes or had gestational diabetes when you were pregnant. Learn more about risk factors for type 2 diabetes.
Currently, no fully artificial pancreas system has been approved by the FDA for use in the U.S. The most advanced product on the market in the USA is currently Medtronic’s MiniMed system which can automatically suspend insulin delivery when it detects low blood sugars. The next generation of their system will anticipate low blood sugars and stop insulin delivery in advance.
This content is provided as a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The NIDDK translates and disseminates research findings through its clearinghouses and education programs to increase knowledge and understanding about health and disease among patients, health professionals, and the public. Content produced by the NIDDK is carefully reviewed by NIDDK scientists and other experts.